Apr 17, 2025, 23:30
Kevin Conroy: JAMA Oncology publication confirms Oncotype DX test reliability across racial and ethnic groups
Kevin Conroy, Chairman and CEO at Exact Sciences, shared a post on LinkedIn:
“An important new comprehensive review published in JAMA Oncology confirms that the Oncotype DX test provides accurate information to help guide breast cancer treatment decisions regardless of race or ethnicity.
Precision medicine should benefit everyone. This growing body of evidence reinforces the trust physicians and patients place in the Oncotype DX test and the critical role it plays in delivering more informed, individualized care.”
More posts featuring Kevin Conroy.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 2, 2025, 00:00
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32